☰

Sahar A. Saddoughi, Ph.D. - Publications

Affiliations: 
2013 Medical University of South Carolina, Charleston, SC, United States 
Area:
General Biology, Molecular Biology, Oncology
Tree Info Similar researchers PubMed Report error

16 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2013 Neviani P, Harb JG, Oaks JJ, Santhanam R, Walker CJ, Ellis JJ, Ferenchak G, Dorrance AM, Paisie CA, Eiring AM, Ma Y, Mao HC, Zhang B, Wunderlich M, May PC, ... ... Saddoughi SA, et al. PP2A-activating drugs selectively eradicate TKI-resistant chronic myeloid leukemic stem cells. The Journal of Clinical Investigation. 123: 4144-57. PMID 23999433 DOI: 10.1172/Jci68951  0.658
2013 Oaks JJ, Santhanam R, Walker CJ, Roof S, Harb JG, Ferenchak G, Eisfeld AK, Van Brocklyn JR, Briesewitz R, Saddoughi SA, Nagata K, Bittman R, Caligiuri MA, Abdel-Wahab O, Levine R, et al. Antagonistic activities of the immunomodulator and PP2A-activating drug FTY720 (Fingolimod, Gilenya) in Jak2-driven hematologic malignancies. Blood. 122: 1923-34. PMID 23926298 DOI: 10.1182/Blood-2013-03-492181  0.697
2013 Saddoughi SA, Ogretmen B. Diverse functions of ceramide in cancer cell death and proliferation. Advances in Cancer Research. 117: 37-58. PMID 23290776 DOI: 10.1016/B978-0-12-394274-6.00002-9  0.664
2013 Saddoughi SA, Gencer S, Peterson YK, Ward KE, Mukhopadhyay A, Oaks J, Bielawski J, Szulc ZM, Thomas RJ, Selvam SP, Senkal CE, Garrett-Mayer E, De Palma RM, Fedarovich D, Liu A, et al. Sphingosine analogue drug FTY720 targets I2PP2A/SET and mediates lung tumour suppression via activation of PP2A-RIPK1-dependent necroptosis. Embo Molecular Medicine. 5: 105-21. PMID 23180565 DOI: 10.1002/Emmm.201201283  0.767
2012 Meyers-Needham M, Lewis JA, Gencer S, Sentelle RD, Saddoughi SA, Clarke CJ, Hannun YA, Norell H, da Palma TM, Nishimura M, Kraveka JM, Khavandgar Z, Murshed M, Cevik MO, Ogretmen B. Off-target function of the Sonic hedgehog inhibitor cyclopamine in mediating apoptosis via nitric oxide-dependent neutral sphingomyelinase 2/ceramide induction. Molecular Cancer Therapeutics. 11: 1092-102. PMID 22452947 DOI: 10.1158/1535-7163.Mct-11-0705  0.702
2011 Simon GR, Saddoughi S, Mukhopadhyay A, Peterson Y, Senkal CE, Oaks J, Perrotti D, Hannun Y, Ogretmen B. Targeting I2PP2A by FTY720: A novel, mechanism-based treatment strategy for patients with advanced and previously treated non-small cell lung cancer (NSCLC). Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 29: 7574. PMID 28023125 DOI: 10.1200/Jco.2011.29.15_Suppl.7574  0.768
2011 Shirai K, Saddoughi S, O'Brien PE, Afrin L, Garrett-Mayer E, Simon GR, Chaudhary UB, Ogretmen B. Serum C18-ceramide as a biomarker for response: Phase II trial of gemcitabine plus doxorubicin in patients with HNSCC. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 29: 5590. PMID 28022062 DOI: 10.1200/Jco.2011.29.15_Suppl.5590  0.592
2011 Senkal CE, Ponnusamy S, Manevich Y, Meyers-Needham M, Saddoughi SA, Mukhopadyay A, Dent P, Bielawski J, Ogretmen B. Alteration of ceramide synthase 6/C16-ceramide induces activating transcription factor 6-mediated endoplasmic reticulum (ER) stress and apoptosis via perturbation of cellular Ca2+ and ER/Golgi membrane network. The Journal of Biological Chemistry. 286: 42446-58. PMID 22013072 DOI: 10.1074/Jbc.M111.287383  0.766
2011 Saddoughi SA, Garrett-Mayer E, Chaudhary U, O'Brien PE, Afrin LB, Day TA, Gillespie MB, Sharma AK, Wilhoit CS, Bostick R, Senkal CE, Hannun YA, Bielawski J, Simon GR, Shirai K, et al. Results of a phase II trial of gemcitabine plus doxorubicin in patients with recurrent head and neck cancers: serum C₁₈-ceramide as a novel biomarker for monitoring response. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 17: 6097-105. PMID 21791630 DOI: 10.1158/1078-0432.Ccr-11-0930  0.721
2011 Salas A, Ponnusamy S, Senkal CE, Meyers-Needham M, Selvam SP, Saddoughi SA, Apohan E, Sentelle RD, Smith C, Gault CR, Obeid LM, El-Shewy HM, Oaks J, Santhanam R, Marcucci G, et al. Sphingosine kinase-1 and sphingosine 1-phosphate receptor 2 mediate Bcr-Abl1 stability and drug resistance by modulation of protein phosphatase 2A. Blood. 117: 5941-52. PMID 21527515 DOI: 10.1182/Blood-2010-08-300772  0.642
2011 Oaks JJ, Mukhopadhyay A, Santhanam R, Saddoughi SA, Neviani P, Harb JG, Ogretmen B, Bittman R, Levine RL, Quintás-Cardama A, Marcucci G, Perrotti D. FTY720 Restores PP2A Tumor Suppressor Activity in Polycythemia Vera CD34+ Progenitors Through Inhibition of Jak2 V617F- and PI-3Kγ-Dependent SET Serine Phosphorylation and Enhancement of NOS-Dependent PP2A Tyrosine Nitration Blood. 118: 2494-2494. DOI: 10.1182/Blood.V118.21.2494.2494  0.683
2010 Ponnusamy S, Meyers-Needham M, Senkal CE, Saddoughi SA, Sentelle D, Selvam SP, Salas A, Ogretmen B. Sphingolipids and cancer: ceramide and sphingosine-1-phosphate in the regulation of cell death and drug resistance. Future Oncology (London, England). 6: 1603-24. PMID 21062159 DOI: 10.2217/Fon.10.116  0.782
2010 Oaks JJ, Mukhopadhyay A, Santhanam R, Saddoughi SA, Walker C, Neviani P, Harb JG, Ma Y, Verstovsek S, Marcucci G, Briesewitz R, Bittman R, Chen C, Quintas-Cardama A, Ogretmen B, et al. Pharmacologic Restoration of PP2A Activity and Interference with the SET-PP2A Interplay by FTY720 and Its Non-Immunosuppressive Derivative as a Novel and Efficient Therapy for Ph-Negative Myeloproliferative Disorders Blood. 116: 775-775. DOI: 10.1182/Blood.V116.21.775.775  0.683
2010 Saddoughi S, Mukhopadhyay A, Ogretmen B. Abstract A26: Direct interaction between ceramide and SET/I2PP2A restores nuclear PP2A activity leading to the degradation of cMyc and suppression of lung tumor growth Clinical Cancer Research. 16. DOI: 10.1158/1078-0432.Tcme10-A26  0.679
2009 Mukhopadhyay A, Saddoughi SA, Song P, Sultan I, Ponnusamy S, Senkal CE, Snook CF, Arnold HK, Sears RC, Hannun YA, Ogretmen B. Direct interaction between the inhibitor 2 and ceramide via sphingolipid-protein binding is involved in the regulation of protein phosphatase 2A activity and signaling. Faseb Journal : Official Publication of the Federation of American Societies For Experimental Biology. 23: 751-63. PMID 19028839 DOI: 10.1096/Fj.08-120550  0.778
2008 Saddoughi SA, Song P, Ogretmen B. Roles of bioactive sphingolipids in cancer biology and therapeutics. Sub-Cellular Biochemistry. 49: 413-40. PMID 18751921 DOI: 10.1007/978-1-4020-8831-5_16  0.692
Show low-probability matches.